Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients
Annals of Oncology, 08/08/2012
Fontein DBY et al. – Some AEs associated with estrogen depletion are related to better outcomes and may be valuable biomarkers in AI treatment.
Methods- Efficacy end points were relapse-free survival (RFS), overall survival (OS) and breast cancer-specific mortality (BCSM), starting at 6 months after starting EXE treatment.
- AEs reported in the first 6 months of treatment were included.
- Specific AEs comprised HF and/or MSAE. Landmark analyses and Cox proportional hazards models assessed survival differences up to 5 years.
- A total of 1485 EXE patients were included. Patients with HF had a better RFS than patients without HF [multivariate hazard ratio (HR) 0.393, 95% confidence interval (CI) 0.19–0.813; P = 0.012].
- The occurrence of MSAE versus no MSAE did not relate to better RFS (multivariate HR 0.677, 95% CI 0.392–1.169; P = 0.162).
- Trends were maintained for OS and BCSM.
- Quantitative hormone receptor expression was not associated with specific AEs.
